vs
Dominari Holdings Inc.（DOMH）与Sight Sciences, Inc.（SGHT）财务数据对比。点击上方公司名可切换其他公司
Dominari Holdings Inc.的季度营收约是Sight Sciences, Inc.的1.5倍（$30.1M vs $20.4M），Sight Sciences, Inc.净利率更高（-20.4% vs -438.1%，领先417.7%），Dominari Holdings Inc.同比增速更快（220.4% vs 6.9%），过去两年Dominari Holdings Inc.的营收复合增速更高（369.1% vs 2.9%）
Sight Sciences, Inc.是一家处于商业化阶段的医疗科技企业，专注于开发及商业化青光眼、干眼症等常见眼部疾病的创新治疗产品，提供微创手术设备与非手术护理解决方案，主要服务美国市场的眼科医师及患者。
DOMH vs SGHT — 直观对比
营收规模更大
DOMH
是对方的1.5倍
$20.4M
营收增速更快
DOMH
高出213.5%
6.9%
净利率更高
SGHT
高出417.7%
-438.1%
两年增速更快
DOMH
近两年复合增速
2.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.1M | $20.4M |
| 净利润 | $-131.8M | $-4.2M |
| 毛利率 | — | 87.3% |
| 营业利润率 | -8.9% | -18.0% |
| 净利率 | -438.1% | -20.4% |
| 营收同比 | 220.4% | 6.9% |
| 净利润同比 | -12426.2% | 64.9% |
| 每股收益（稀释后） | $-6.94 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMHSGHT
| Q4 25 | $30.1M | $20.4M | ||
| Q3 25 | $50.8M | $19.9M | ||
| Q2 25 | $34.1M | $19.6M | ||
| Q1 25 | $8.1M | $17.5M | ||
| Q4 24 | $9.4M | $19.1M | ||
| Q3 24 | $4.0M | $20.2M | ||
| Q2 24 | $6.2M | $21.4M | ||
| Q1 24 | $1.4M | $19.3M |
净利润DOMHSGHT
| Q4 25 | $-131.8M | $-4.2M | ||
| Q3 25 | $125.2M | $-8.2M | ||
| Q2 25 | $16.6M | $-11.9M | ||
| Q1 25 | $-32.5M | $-14.2M | ||
| Q4 24 | $1.1M | $-11.8M | ||
| Q3 24 | $-4.2M | $-11.1M | ||
| Q2 24 | $-6.1M | $-12.3M | ||
| Q1 24 | $-5.4M | $-16.3M |
毛利率DOMHSGHT
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
营业利润率DOMHSGHT
| Q4 25 | -8.9% | -18.0% | ||
| Q3 25 | -3.1% | -39.7% | ||
| Q2 25 | -57.0% | -59.6% | ||
| Q1 25 | -394.6% | -79.2% | ||
| Q4 24 | 0.4% | -62.5% | ||
| Q3 24 | -79.1% | -55.7% | ||
| Q2 24 | -44.3% | -59.2% | ||
| Q1 24 | -205.2% | -76.4% |
净利率DOMHSGHT
| Q4 25 | -438.1% | -20.4% | ||
| Q3 25 | 246.4% | -41.0% | ||
| Q2 25 | 48.7% | -61.0% | ||
| Q1 25 | -400.5% | -80.8% | ||
| Q4 24 | 11.4% | -62.1% | ||
| Q3 24 | -104.2% | -54.9% | ||
| Q2 24 | -99.1% | -57.7% | ||
| Q1 24 | -398.0% | -84.4% |
每股收益（稀释后）DOMHSGHT
| Q4 25 | $-6.94 | $-0.07 | ||
| Q3 25 | $7.27 | $-0.16 | ||
| Q2 25 | $1.12 | $-0.23 | ||
| Q1 25 | $-3.02 | $-0.28 | ||
| Q4 24 | $0.21 | $-0.23 | ||
| Q3 24 | $-0.67 | $-0.22 | ||
| Q2 24 | $-1.01 | $-0.25 | ||
| Q1 24 | $-0.91 | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.5M | $92.0M |
| 总债务越低越好 | — | $42.4M |
| 股东权益账面价值 | $69.4M | $63.9M |
| 总资产 | $112.9M | $115.3M |
| 负债/权益比越低杠杆越低 | — | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资DOMHSGHT
| Q4 25 | $80.5M | $92.0M | ||
| Q3 25 | $176.2M | $92.4M | ||
| Q2 25 | $28.2M | $101.5M | ||
| Q1 25 | $18.9M | $108.8M | ||
| Q4 24 | $8.2M | $120.4M | ||
| Q3 24 | $7.2M | $118.6M | ||
| Q2 24 | $12.1M | $118.2M | ||
| Q1 24 | $7.1M | $127.3M |
总债务DOMHSGHT
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
股东权益DOMHSGHT
| Q4 25 | $69.4M | $63.9M | ||
| Q3 25 | $210.2M | $64.3M | ||
| Q2 25 | $88.6M | $70.0M | ||
| Q1 25 | $42.4M | $77.6M | ||
| Q4 24 | $39.9M | $87.5M | ||
| Q3 24 | $38.3M | $95.0M | ||
| Q2 24 | $42.4M | $101.6M | ||
| Q1 24 | $47.7M | $109.2M |
总资产DOMHSGHT
| Q4 25 | $112.9M | $115.3M | ||
| Q3 25 | $223.4M | $116.3M | ||
| Q2 25 | $109.3M | $122.0M | ||
| Q1 25 | $52.3M | $129.7M | ||
| Q4 24 | $47.1M | $142.8M | ||
| Q3 24 | $43.4M | $143.6M | ||
| Q2 24 | $49.1M | $149.7M | ||
| Q1 24 | $52.2M | $155.6M |
负债/权益比DOMHSGHT
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.7M | $-1.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-2.0M |
| 自由现金流率自由现金流/营收 | — | -9.7% |
| 资本支出强度资本支出/营收 | — | 0.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOMHSGHT
| Q4 25 | $22.7M | $-1.8M | ||
| Q3 25 | $-4.9M | $-8.7M | ||
| Q2 25 | $-353.0K | $-7.5M | ||
| Q1 25 | $1.2M | $-11.6M | ||
| Q4 24 | $-16.7M | $-3.5M | ||
| Q3 24 | $-4.7M | $362.0K | ||
| Q2 24 | $1.4M | $-9.5M | ||
| Q1 24 | $-8.6M | $-9.8M |
自由现金流DOMHSGHT
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
自由现金流率DOMHSGHT
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
资本支出强度DOMHSGHT
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
现金转化率DOMHSGHT
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
